20.4% CagriSema Trial REDEFINE 2 (NEJM 2025) Duration 68 weeks Population T2D + BMI 27 (n=1,206) Mean Weight Loss 13.7% CagriSema vs 3.4% placebo
Konkalmatt PR, Asico LD, Zhang Y, Yang Y, Drachenberg C, Zheng X, Han F, Jose PA, Armando I
Das kann therapeutisch sinnvoll sein, wenn ein Medikament sauber entwickelt, geprft, dosiert, hergestellt und berwacht wird
This dual-receptor activity distinguishes cagrilintide from single-receptor agonists examined in metabolic research
after reconstitution, refrigerate and use within ~30 days
Meanwhile, the broader senolytic field has advanced dasatinib+quercetin has completed multiple human trials including Phase 2 in Nature Medicine (Farr 2024)